| Reducing venous thromboembolism after elective neurosurgery1
|
Enoxaparin vs. placebo |
Pulmonary embolism (PE) or deep venous Thrombosis (DVT) |
8 days |
33 |
17 |
7 (4 to 18) |
| PE or proximal DVT |
14 |
5 |
12 (6 to 73) |
| Overall DVT |
32 |
17 |
7 (4 to 20) |
| Proximal DVT |
13 |
5 |
13 (7 to 143) |
| Stroke in children with sickle-cell anaemia; periodic blood transfusions2 |
Transfusion vs. standard care |
All strokes |
20 months |
16 |
2 |
7 (4 to 18) |
| Cerebral infarction |
15 |
2 |
8 (5 to 22) |
| Idiopathic venous thromboembolism3 |
Warfarin vs. placebo |
Recurrent venous thromboembolism |
3 months |
20.5 |
1.3 |
6 (3 to 9) |
| Total bleeding |
1.2 |
11.4 |
10 (5 to 30) |
| Pulmonary embolism and proximal deep venous thrombosis (DVT)4
|
Subcutaneous low-molecular-weight heparin (tinzaparin sodium) vs. unfractionated heparin (control) |
Recurrent venous thromboembolism |
3 months |
6.8 |
0 |
15 (8 to 36) |
| Major bleeding |
1.9 |
1.0 |
Not significant |
| Minor bleeding |
2.9 |
1.0 |
Not significant |
| Death |
8.7 |
6.2 |
Not significant |
